Forward P/S Multiple: BIOLASE (BIOL)

BIOLASE, Inc. - graphic logo of issuer BIOL

Delisting risks and losses driven by clinic conservatism are weighing on quotes, which the GURU.Markets daily chart reflects via the projected revenue multiple, where 0.00 is the current level of the indicator. However, BIOLASE, Inc. (BIOL) maintains its status as a leader in laser dentistry, and the painless nature of Waterlase procedures keeps the product in demand within the premium segment, while the company's R&D focus on tissue micro-processing ensures its technological superiority.

biolase.com - BIOL Market Cap to Projected Revenue (period 07/04/2022 - 08/04/2024)

Summary analytical data breakdowns for Biolase Inc. (BIOL)

- market price and analyst price targets:
Price Chart BIOLASE|BIOL - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Biolase Inc.|BIOL - Total Enterprise Value
- issuer book value statistics:
Book Value per Share BIOLASE|BIOL - Accounting Capitalization|Market Capitalization to Book Value Ratio biolase.com|BIOL - Company Total Asset Base
- debt and liquidity data:
Total Debt to Capital BIOLASE, Inc.|BIOL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital BIOLASE, Inc.|BIOL - Company Aggregate Debts|Debt to Book Capitalization Ratio Biolase Inc.|BIOL - Company Long-Term Debt|Company Current Liabilities BIOLASE|Quick Ratio biolase.com
- financial results and valuation multiples details:
BIOL - Company Net Income|Expected Profit BIOLASE, Inc.|BIOL - Market Cap to Net Income Ratio|Projected Price to Earnings Biolase, Inc.|BIOL - PEG Multiple|EV/EBITDA Multiple Biolase Inc.|BIOL - Operating income before deduction of amortization|Earnings per share for the last twelve months BIOLASE|BIOL - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months biolase.com|BIOL - Net earnings per share growth this year|Earnings growth forecast for next year BIOLASE, Inc.
- sales and revenue indicators:
BIOL - Company Total Revenue|Company Projected Revenue BIOLASE|BIOL - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Biolase Inc.
Fundamental company analysis:BIOL (BIOLASE)
Product sample of Biolase Inc.

The forward P/S ratio determines the cost of one dollar of projected revenue, reflecting market expectations regarding future cash flows. By analyzing the forward P/S valuation, an investor can observe the revenue discount trend, which is critical for BIOLASE, Inc. (BIOL), where high switching costs create barriers for competitors, while the slow adoption of lasers in dentistry limits the growth rate of its market capitalization.

Who BIOLASE, Inc. competes with

Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple ClearPoint (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD Inc. - Price to Expected Revenue Ratio|ZJYL: Forward P/S Multiple|VANI (Vivani Medical) - Price-to-Projected Revenue Ratio|XTNT (Xtant Medical Holdings, Inc.) - Forward P/S Multiple|NeuroOne (NMTC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Modular Medical (MODD)|MYO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Envoy Medical, Inc. COCH|vivoslife.com - Price-to-Projected Revenue Ratio|enVVeno Medical Corp. - Forward P/S Multiple|SINT - Forward P/S Multiple|Tenon Medical, Inc (TNON) - Price-to-Projected Revenue Ratio|LFWD - Market Cap to Expected Sales Ratio|AMIX (Autonomix Medical Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio invobioscience.com IVF|Forward Price-to-Revenue Multiple BBLG (Bone Biologics Corp)|AXNX (Axonics Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (Dynatronics)|Market Cap to Expected Sales Ratio Paragon 28 Inc. (FNA)|INVO - Price-to-Projected Revenue Ratio